Cell Therapy Market Size, Share & Trends Analysis Report By Use-type, By Therapy Type, By Region And Segment Forecasts From 2021 To 2028

Report ID: MN17620367  |  Published: November 2022  |  No of Pages: 120
Format: Electronic (PDF)  |  Industry: Biotechnology

The global cell therapy market size was valued at USD 7.8 billion in 2020 and is projected to expand at a CAGR of 14.5% from 2021 to 2028. The market is predominantly driven by the staggering rise in the number of clinical research on cell-based therapies. The regenerative medicine field is showcasing numerous developments such as cell-based therapies for treating chronic ailments.

The regenerative medicine field is going through a series of technological advancements aimed at improving diagnoses and therapies for chronic ailments. A single product can be used to provide a strong portfolio of candidates primarily through the introduction of proprietary cell lines, according to this theory. For instance, Immunicum uses T-cell primers, chimeric antigen receptor T cell (CAR-T) expansion, and dendritic cell neoantigen presentation technology to expand their product line for Immuno-oncology.

In addition, direct cell reprogramming has also drawn a lot of interest as a cutting-edge therapeutic approach owing to its efficacy and safety. Fortuna Fix, a privately held company, is planning to employ patient neural stem cells produced through direct reprogramming to restore lost neuronal tissue in cases of dementia or neurotrauma. This will make Fortuna Fix the first company to use patient neural stem cells clinically. These current initiatives are anticipated to strengthen the product portfolio in the market.

The market players are receiving U.S. FDA approvals for their wide portfolio of therapies for treating a range of diseases. For instance, Stemedica Cell Technologies, Inc. received FDA approval for an investigational new drug in September 2020 to begin its phase II trials using intravenously delivered allogeneic MSCs in Covid-19 patients. Ischemic-tolerant MSCs are a promising biological therapy for COVID-19 due to their immunomodulatory effects, minimal immunogenicity, and ability to reduce too pro-inflammatory responses, among other characteristics.

The top regional players in Canada are keen on capitalizing on the untapped potential for designing innovative therapeutic procedures. For example, RepliCel recently announced its investments in regenerative medicine development projects. Furthermore, in February 2021, the company publically rolled out its plans for the clinical testing and commercialization of its three new technologies in Japan, which include cell-based therapies - one for tendon regeneration and the other for skin rejuvenation.

Cell Therapy Market Report Key Takeaways

  • Based on use-type, the research-use segment accounted for a share of 60.9% in 2020 owing to the growing use of cell-based therapies for replacing, restoring, repairing, or regenerating damaged cells, tissues, and organs
  • Mesenchymal Stem Cells (MSCs) have demonstrated the potential related to the moderation of the immune system. MSCs piqued the interest of medical professionals during the 2020 COVID-19 spike
  • The clinical-use segment is projected to expand at a CAGR of 13.4% by 2030 due to the steady penetration of this segment. The cell therapies approved for clinical use include CARTISTEM, MACI, Invossa, Epicel, Cupistem, Cellgram-AMI, Cellistem IC, Prochymal, GINTUIT, and Imlygic. This will encourage other companies to invest in the clinical-use segment
  • Based on therapy, the autologous therapies segment captured a market share of 53.2% in 2020 and is estimated to continue its dominance over the global cell therapy market by 2030
  • Geographically, Asia Pacific is set to emerge as the fastest-growing regional market by 2030 and register a lucrative CAGR of 15.52% during the forecasts period


Cell Therapy Market Segments

  • Cell Therapy Use-type Outlook (Revenue, USD Million, 2017 - 2028)
    • Clinical-use
      • By Therapeutic Area
        • Malignancies
        • Muscoskeletal Disorders
        • Autoimmune Disorders
        • Dermatology
        • Others
      • By Cell Type
        • Stem Cell Therapies
          • BM, Blood, & Umbilical cord-derived Stem Cells
          • Adipose-derived cells
          • Others
        • Non-stem Cell Therapies
    • Research-use
  • Cell Therapy Type Outlook (Revenue, USD Million, 2017 - 2028)
    • Allogenic Therapies
    • Autologous Therapies
  • Cell Therapy Regional Outlook (Revenue, USD Million, 2017 - 2028)
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • U.K.
    • Asia Pacific
      • China
      • Japan
    • Latin America
      • Brazil
    • Middle East & Africa
      • South Africa
  • List of Key Players in the Cell Therapy Market
    • Kolon TissueGene, Inc.
    • Anterogen Co., Ltd.
    • JCR Pharmaceuticals Co., Ltd. 
    • Castle Creek Biosciences, Inc.
    • The Future of Biotechnology, MEDIPOST
    • Osiris Therapeutics, Inc.
    • PHARMICELL Co., Ltd
    • Tameika Cell Technologies, Inc.
    • Cells for Cells
    • NuVasive, Inc.
    • Vericel Corporation
    • Celgene Corporation
What questions do you have? Get quick response from our industry experts. Request More information
Key questions answered in the report include
key questions
We also offers customization on reports based on specific client requirement.
Request for Customization

Choose License Type

Research Assistance

Ryan Manuel
Ryan Manuel

Research Support Specialist, USA

  1. Phone: +1-408-610-2300
  2. Toll Free: +1-866-831-4085
  3. Email: [email protected]
Connect With Expert
  • World's largest premium report database
  • Transparent pre & post sale customer engagement model
  • Unparalleled flexibility in terms of rendering services
  • Safe & secure web experience
  • 24*5 Research support service

Get a Free Sample

FREE sample contains market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...